Table 1.
Demographics of study participants.
| Variable | Noncritical, n = 453 (%) | Critical, n = 193 (%) | p |
|---|---|---|---|
| Age | <0.001 | ||
| <33 | 155 (34.2) | 12 (6.2) | |
| 34–43 | 138 (30.5) | 31 (16.1) | |
| 44–55 | 92 (20.3) | 60 (31.1) | |
| >56 | 68 (15.0) | 90 (46.6) | |
| Sex | 0.217 | ||
| Male | 305 (77.2) | 70 (83.3) | |
| Female | 90 (22.8) | 14 (16.7) | |
| Body mass index (kg/m2 of body surface area) | 0.001 | ||
| <18.50 | 9 (2.3) | 1 (0.5) | |
| 18.51–24.90 | 115 (29.4) | 38 (19.7) | |
| 24.91–29.99 | 168 (43.0) | 77 (39.9) | |
| >30.00 | 99 (25.3) | 77 (39.9) | |
| Country of origin | 0.004 | ||
| Middle Eastern | 40 (30.9) | 80 (41.5) | |
| Asian | 290 (64.0) | 103 (53.4) | |
| African | 18 (4.0) | 3 (1.6) | |
| European | 2 (0.4) | 5 (2.6) | |
| American | 3 (0.7) | 2 (1.0) | |
| History of comorbid condition | <0.001 | ||
| No | 263 (65.1) | 75 (40.3) | |
| Yes | 141 (34.9) | 111 (59.7) | |
| Diabetes | <0.001 | ||
| No | 279 (75.4) | 78 (47.3) | |
| Yes | 91 (24.6) | 87 (52.7) | |
| Immunosuppressive condition | 0.20 | ||
| No | 250 (93.6) | 117 (90.0) | |
| Yes | 17 (6.4) | 13 (10.0) | |
| Liver disease | 0.01 | ||
| No | 323 (99.4) | 128 (96.2) | |
| Yes | 2 (0.6) | 5 (3.8) | |
| Metabolic disease | <0.001 | ||
| No | 318 (95.8) | 112 (83.0) | |
| Yes | 14 (4.2) | 23 (17.0) | |
| Neurological disorder | 0.03 | ||
| No | 320 (98.8) | 126 (95.5) | |
| Yes | 4 (1.2) | 6 (4.5) | |
| Renal disease | <0.001 | ||
| No | 312 (94.8) | 111 (78.7) | |
| Yes | 17 (5.2) | 30 (21.3) | |
| Cardiac condition | <0.001 | ||
| No | 312 (91.5) | 111 (76.0) | |
| Yes | 29 (8.5) | 35 (24.0) | |
| Chronic lung condition | <0.001 | ||
| No | 318 (97.2) | 113 (86.3) | |
| Yes | 9 (2.8) | 18 (13.7) |